News and Trends 20 Dec 2022
Verona Pharma drug meets COPD phase 3 trial endpoints
Verona Pharma plc has announced positive results of its phase 3 ENHANCE-1 trial evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The ENHANCE-1 trial successfully…